Antiviral Vaccines

Pig Parvo VLPs Elicit Protective Antiviral CTLs

Published in Hepatitis Weekly, July 28th, 1997

A new type of antigen-bearing virus-like particle (VLP) is the first to induce protection - in the absence of adjuvant - against in vivo challenge with a lethal virus.

The new VLPs are dubbed porcine parvovirus (PPV) virus-like particles or PPV:VLP.

"To our knowledge, the present study demonstrates for the first time that nonreplicative parvovirus-like particles carrying a single viral CTL [cytotoxic lymphocyte] epitope are able to induce complete protection of mice against a lethal viral infection through the induction of virus-specific MHC class I-restricted CD8⁺ CTLs," wrote C. Sedlik of the Pasteur Institute, Paris, France, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1997-07-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry